NCT02057107View on ClinicalTrials.gov

SBRT With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated SCCHN

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 3, 2013

Primary Completion Date

March 15, 2019

Study Completion Date

December 31, 2019

Conditions
Previously-IrradiatedSquamous Cell Carcinoma of the Head and Neck Cancer
Interventions
RADIATION

SBRT

8.8-10 Gy per fraction (total: 44-50 Gy)

DRUG

Cetuximab

"Day -7 (One week prior to commencement of stereotactic radiosurgery):~Cetuximab, 400 mg/m2~Days 0 and 8 (The 1st and 2nd week of radiosurgery):~Cetuximab, 250 mg/m2 Cetuximab, 250 mg/m2 will be given weekly ( following radiosurgery)"

DRUG

Docetaxel

Days 0 and 8 (The 1st and 2nd week of radiosurgery) Docetaxel, 25 mg/m2 Docetaxel, 25 mg/m2 will be given weekly (following radiosurgery)

Trial Locations (1)

15232

UPMC Hillman Cancer Center - Radiation Oncology, Pittsburgh

Sponsors

Lead Sponsor

Heath Skinner
All Listed Sponsors
lead

Heath Skinner

OTHER

NCT02057107 - SBRT With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated SCCHN | Biotech Hunter | Biotech Hunter